Introduction
Peripheral neuropathy (PN) is one of the most common neurologic complications of HIV infection, affecting 20% to 50% of patients and often causing symptoms of distal predominant sensory loss, paresthesias, and neuropathic pain [1, 2] . Studies of the natural history of HIV-associated PN (HIV-PN) suggest that it tends to be static over time, without significant worsening in objective findings on neurologic examination or other testing such as nerve conduction studies and quantitative sensory testing [3] . However, HIV-PN is also unlikely to spontaneously remit, and so as HIV has become a chronic disease, and with the epidemic having entered the latter half of its fourth decade, there are now numerous patients who have been living with the chronic painful stimulus of HIV-PN for many years. Chronic multifocal and widespread pain syndromes are known to be common in HIV, and outside the realm of HIV, at least one other form of neuropathy, idiopathic small-fiber neuropathy, has been associated with a chronic widespread pain syndrome (i.e., fibromyalgia) [4, 5] . However, it is unknown whether HIV-PN is associated with other pain syndromes, information that could be directly relevant to HIV-PN treatment choices and clinical trial design.
In the present study, we used a clinical data warehouse (CDW) maintained by our institution to examine a potential link between PN and chronic pain in HIV by determining whether patients with a diagnosis of HIV-PN were more likely to experience other chronic pain syndromes. As we have described previously, the CDW extracts and aggregates information from the electronic health record (EHR) into a de-identified, searchable format. We reasoned that establishing a link between HIV-PN and other chronic pain syndromes in HIV would be useful for both researchers and clinicians. In terms of research, establishing efficacy of medications for the treatment of neuropathic pain in HIV-PN has been very difficult; if HIV-PN often occurs as part of a more complex pain syndrome, this knowledge might alter therapeutic strategies and study design. Such knowledge might also provide a rationale for exploring central pain sensitization as an epiphenomenon of chronic HIV. In the clinic, knowledge that the patient presenting with HIV-PN likely has other pain issues might help physicians provide more comprehensive and appropriate pain management services.
Methods

Patients
Patients included in this study were all receiving primary care including combination antiretroviral therapy (CART) at our institution's HIV clinic, which is located in the East Harlem neighborhood of New York City and serves a predominantly minority, low-income patient population. All data were obtained from the CDW maintained by our institution. The CDW contains information from 2003 to the present, from over 3 million patient records, and uploads data daily from our institution's comprehensive EHR, which contains all inpatient and outpatient documentation for the entire medical center. During the data upload, all protected health information is removed, and the patient is assigned a unique CDW identification number. Patients included in the study were between age 18 and 65 years and had at least three visits to the clinic during the preceding 12 months. Regarding the protection of human subjects, the CDW is compliant with the Health Insurance Portability and Accountability Act (HIPAA), New York State privacy and security regulations, and the policies of the Institutional Review Board (IRB) of the Icahn School of Medicine at Mount Sinai. Accordingly, research projects using its deidentified data are exempt from additional individual review.
Data Collection and Statistical Analyses
Basic clinical data extracted from the CDW included demographics (age, race, ethnicity, and gender) and the most recent values for CD4þ cell count and plasma HIV-1 viral load. We also extracted data on the presence of key medical, psychiatric, and substance use comorbidities, as well as laboratory values (e.g., hemoglobin, platelets, ALT, and AST) needed to calculate the Veteran's Aging Cohort Study (VACS) index [6] . The VACS index has been used as a marker of burden of illness in HIV-infected patients and has been shown to predict mortality. Diagnoses of HIV-PN and other chronic pain disorders were established by searching for relevant International Classification of Disease, Ninth and Tenth Revision (ICD-9/10), codes. Relevant codes were established based on the diagnoses listed in the International Association for the Study of Pain (IASP) Classification of Chronic Pain, which is a comprehensive, consensus-approved manifest of chronic pain syndromes. The details of this process and the full list of codes have been previously published [7] .
Descriptive statistics and measures of center were calculated using percentages for categorical variables, means and standard deviations for normally distributed variables, and medians and interquartile ranges for continuous non-normally distributed variables. Univariate analyses (independent samples t test, Wilcoxon rank sum, or v 2 , as appropriate) were first performed to discern differences between groups with and without HIV-PN. We then performed binary logistic regression to determine whether HIV-PN was associated with the presence of at least one comorbid pain syndrome after controlling for relevant confounders (i.e., factors found to be associated with HIV-PN in univariate analyses, or previously shown to be associated with chronic pain). We then focused only on the group with HIV-PN, using similar analyses to determine whether there were differences between the groups with and without a comorbid pain diagnosis. All analyses were two-tailed and performed at the P ¼ 0.05 level of significance using SPSS version 22.
Results
Sample Characteristics
Six hundred and thirty-eight patients met eligibility criteria and were included in the analysis. The sample was predominantly minority, with good representation of both men (57%) and women (43%) and a mean age of 48 years (see Table 1 ). In general, HIV was well controlled, with the majority of patients having very low to undetectable viral loads (73% with HIV-1 viral load < 50 copies/mL), and mean CD4þ cell counts of 603 cells/mm 3 .
Comparison of Patients with and without Clinically Diagnosed HIV-PN
Of the 638 patients sampled, 68 (11%) had a diagnosis of HIV-PN. The patients with HIV-PN were older (53 vs 47, t(636) ¼ À3.8, P < 0.001), but there were no differences in other demographic factors, such as gender or race/ethnicity, or in CD4þ cell count or HIV-1 viral load.
Patients with HIV-PN were more likely to have a substance use disorder (49% vs 30%, v 2 ¼ 10.0, P ¼ 0.002), consistent with prior observations that substance use is a risk factor for HIV-PN [8] . In addition, patients with HIV-PN were more likely to have been diagnosed with at least one psychiatric disorder (71% vs 46%, v 2 ¼ 15.0, P < 0.001). This effect was not driven by one particular diagnosis. When the major psychiatric diagnostic categories (i.e., those with >10 patients: schizophrenic, bipolar/manic, depressive, other episodic mood, other psychoses, anxiety, personality, adjustment, post-traumatic stress disorders) were examined individually, the percentage of patients with HIV-PN carrying such a diagnosis was numerically higher for every category except adjustment disorders (which were essentially equal at 5.9% and 6.5%), and the difference was statistically significant (P < 0.05) for four categories (depressive, other episodic mood, post-traumatic stress, and personality disorders). Not surprisingly, a higher percentage of patients with HIV-PN had diabetes (9% vs 4%), and patients with HIV-PN tended to have higher VACS indices (31.2 vs 27.0), indicating an overall greater burden of illness, although neither of these differences was statistically significant.
Patients diagnosed with HIV-PN were more than twice as likely to have a comorbid pain diagnosis than their counterparts without HIV-PN (66% vs 32%, v 2 ¼ 30.3, P < 0.001). The comorbid pain diagnoses (see Figure 1) were diverse and included spinal degenerative disorders (38%), other joint pain (22%), headache disorders (10%), muscular pain (6%), and other/unspecified disorders (16%). This last category consisted primarily of nonspecific pain diagnoses (e.g., "chronic pain") and, to a lesser extent, rare diagnoses such as chronic pelvic pain. When each of these other pain conditions was examined individually, we found that they were all more prevalent in patients with HIV-PN, although not all the differences achieved statistical significance. For example, 36% of patients with HIV-PN had spinal degenerative disorders, compared with 12% of patients without HIV-PN (v 2 ¼ 30.8, P < 0.001). For other joint pain, the difference was 23% vs 13% (v 2 ¼ 5.7, P ¼ 0.017); for headache disorders, the difference was 10% vs 5% (v 2 ¼ 2.4, P ¼ 0.12); for muscular pain, the difference was 6% vs 2% (v 2 ¼ 2.5, P ¼ 0.11); and for other pain disorders, the difference was 16% vs 7% (v 2 ¼ 8.9, P ¼ 0.003). Binary logistic regression was performed to assess the effects of HIV-PN on the likelihood of having a comorbid chronic pain disorder, controlling for age, Figure 1 Breakdown of comorbid pain syndromes in HIV-peripheral neuropathy.
Comorbid Pain Syndromes gender, and psychiatric and substance use disorders. The model was statistically significant (v 2 (5) ¼ 81.38, P < 0.001), explained 16% (Nagelkerke R 2 ) of the variance in comorbid chronic pain, and correctly classified 70% of cases. HIV-PN was the strongest predictor of a comorbid chronic pain syndrome (OR ¼ 3.3, P < 0.001). Psychiatric (OR ¼ 2.4, P < 0.001) and substance use (OR ¼ 1.8, P ¼ 0.002) disorders and female gender (OR ¼ 1.7, P ¼ 0.002) were also independent predictors.
Comparison of Patients with HIV-PN Alone with Those with HIV-PN and a Comorbid Chronic Pain Disorder
We also examined whether among the 68 participants with HIV-PN there were salient features that distinguished those who had comorbid pain diagnoses from those who did not (see Table 2 ). The patients with HIV-PN and a comorbid chronic pain disorder were similar in most regards to the patients with HIV-PN alone. There were no significant differences in age, gender, CD4þ cell count, HIV-1 viral load, VACS index, or the presence of a substance use diagnosis. There was a trend for more African American patients, and there were fewer white patients in the group with comorbid pain. However, the only significant difference between the groups was the presence of a psychiatric diagnosis. The great majority of patients with HIV-PN and a comorbid chronic pain diagnosis also had a psychiatric diagnosis (82%), compared with 48% in the group with HIV-PN alone (v 2 ¼ 8.67, P ¼ 0.003).
Discussion
The goal of this study was to elucidate the degree to which clinically diagnosed HIV-PN is associated with other chronic pain disorders. Using a clinical data warehouse to access data from a large primary care HIV clinic, we identified 638 HIV-infected, CART-treated patients, of whom 11% carried a diagnosis of HIV-PN. The majority (66%) of patients with a diagnosis of HIV-PN had at least one other chronic pain diagnosis, whereas only 32% of patients without HIV-PN had another chronic pain diagnosis. The comorbid pain disorders consisted mostly of musculoskeletal pain (including back pain) and headache disorders. The relationship between HIV-PN and comorbid chronic pain disorders persisted in a multivariate model adjusted for age, gender, and psychiatric and substance use diagnoses. In this model, HIV-PN was the strongest predictor of a comorbid pain diagnosis, conferring greater than threefold odds. We also found that among patients with HIV-PN, the presence of a psychiatric diagnosis was associated with a comorbid chronic pain diagnosis whereas demographic factors and variables reflecting overall burden of illness were not.
Taken together, these findings provide several insights into the experience of HIV-PN in the current HIV treatment era and suggest mechanistic hypotheses that, while not addressed here, could be the topic of future research. One main finding is that a majority of patients with HIV-PN have at least one other pain disorder. This has immediate implications for how clinicians should approach the treatment of HIV-PN. Given the high likelihood that a patient with HIV-PN has comorbid headache or musculoskeletal pain, it is important that clinicians ask patients with HIV-PN about other types of pain and formulate the pain management plan accordingly. Knowledge of a comorbid chronic pain disorder might influence the choice of medication or recommendations for nonpharmacologic treatment such as physical therapy. In addition, given the high prevalence of psychiatric and substance use disorders in these patients, screening for such disorders and arranging for appropriate referral and treatment when they are discovered should be regarded as an integral part of the pain management plan. There are also practical implications for research. Symptomatic treatments, such as pregabalin and the high-dose capsaicin patch, which have proven efficacy in other neuropathic pain disorders, have failed in trials of HIV-PN [9, 10] . It is possible that the high prevalence of comorbid pain diagnoses in these patients, some of which may be unresponsive to treatments targeting neuropathic pain, could confound the reporting of pain intensity and other outcome measures. Better awareness of and accounting for comorbid pain disorders might allow for alterations in trial design that could improve the ability to detect treatment effect.
In addition to these clinical and research implications, our data raise questions regarding pathogenic mechanisms, which cannot be addressed using the current clinical observational data but could be examined in future studies. Due to the cross-sectional nature of the data, we do not know the time course over which patients developed HIV-PN and other painful disorders, including whether or not the HIV-PN preceded the other disorders. However, one possibility is that HIV-PN is a cause of other widespread pain syndromes in HIV. This hypothesis is indirectly supported by literature outside the realm of HIV, which has implicated neuropathies, particularly those involving small fibers, as a potential cause of fibromyalgia in some patients [11, 12] . One potential underlying mechanism is central sensitization, whereby the painful stimulus of PN triggers a remodeling of the central nervous system (CNS), causing an increase in excitability of neurons in the nociceptive pathway via long-term potentiation [13] . This mechanism is supported by studies demonstrating synaptic plasticity in the insular cortex, as well as increased glutamate metabolism and gray matter size in the anterior cingulate cortex, in response to neuropathic pain. Given the important relay connections that the insular cortex and anterior cingulate cortex have with cortical association areas, changes in this pathway could predispose patients with HIV-PN toward the development of other pain syndromes [14] [15] [16] . It has also been proposed that PN might be directly causative of chronic multifocal and widespread pain disorders in some patients, perhaps due to atypical, non-length-dependent distributions of the PN, but this is as of yet unproven [17] .
An alternative explanation for the association of HIV-PN with other chronic pain disorders is that there is no causality, but rather shared underlying mechanisms. A conceptual framework describing the mechanisms of chronic pain in HIV has been proposed, which emphasizes biological, psychological, and social factors that can contribute to chronic pain and are particularly relevant to HIV-infected populations [18] . These include biologic mechanisms of psychiatric illness and substance abuse, the psychological effects of traumatic life events, and social isolation and stigma. The importance of psychological factors in the clinical manifestations of HIV-PN is supported by our finding that among patients with HIV-PN the presence of a psychiatric disorder is associated with a comorbid chronic pain syndrome. It has long been recognized that HIV-PN has a broad spectrum of clinical presentations, from asymptomatic to nonpainful insensate to severe neuropathic pain. It may be that some of this variability arises from differences in psychosocial factors including variables not assessed in this study such as educational level and health literacy, self-efficacy, and perceived disability.
This study has limitations. All patients were receiving care at a single center that serves a predominantly lowincome, urban community, and so findings may not be generalizable to other settings. The data described were obtained from clinical records, and so the accuracy of assigned diagnoses depends on the treating clinician; thus it is possible that the observed associations could be explained, at least in part, by differences in the propensity of different providers to assign pain diagnoses. The observed percentage of patients (11%) with HIV-PN is significantly lower than other studies [19, 20] . Thus it is likely that the use of clinical diagnoses derived from the EMR resulted in an underestimation HIV-PN in this sample. The patients with HIV-PN who are most likely to be missed using this methodology are those who are either asymptomatic or whose symptoms are insufficiently bothersome to be brought to the attention of their provider or whose diagnoses have not yet been entered into the EMR. Thus, our sample of HIV-PN patients likely represents a more severe subset of all patients with HIV-PN. Another limitation is that due to the manner in which data are coded in the CDW, we did not have access to several important variables that we would have otherwise included, particularly duration of HIV infection, CD4þ nadir, past exposure to neurotoxic antiretrovirals, and the duration of HIV-PN and the comorbid pain diagnoses. Strengths of the study include the relatively large sample size and the fact that, owing to the use of the CDW, all eligible clinic patients were included in the overall sample (N ¼ 638), reducing selection bias.
The awareness of chronic pain in HIV patients, including HIV-PN, is increasing. However, whether specific chronic pain diagnoses may have common, HIV-specific underlying mechanisms is still poorly understood. Our study showed an association between HIV-PN and comorbid chronic pain diagnoses. These data, considered together with the concept of central sensitization and other studies demonstrating morphological changes in the brains of patients with HIV and neuropathic pain, indicate that patients with HIV-PN may experience pain differently. Future longitudinal research is needed to fully understand these differences, to determine whether HIV-PN is truly a risk factor for other chronic pain disorders, and to develop strategies for preventing the development of complex chronic pain disorders in HIV.
